Waters Corp (WAT) has seen a series of ups and downs lately. BoA analysts have raised the company's price target while recent Q4 and Q1 earnings have had mixed influences on investor confidence. In Q4 2024, strong Pharma and PFAS growth faced FX challenges, beating on revenue, but the company's quarterly revenue guidance significantly missed expectations. Conversely, Q1 2025 saw robust instrument sales, boosted by increased demand from India for weight-loss drugs, producing an upbeat sales guidance for the next quarter. Notably, WAT's financials have remained strong despite weak stock performance. Waters Corp acquired Halo Labs, broadening its biological analysis portfolio, and launched its industry-first smart HPLC system which boasts 40% fewer errors and revolutionary security features. Also, a new benchmark was set for high-throughput labs with the Xevo TQ Absolute XR Mass Spectrometer. The corporation's stock currently seems to be underperforming against some indexes, such as the Dow and the healthcare sector, but has been tagged a top growth stock in light of its long-term potential. A strategic SWOT insight indicates future growth amid a booming biotech market.
Waters Corp WAT News Analytics from Wed, 17 Jun 2020 07:00:00 GMT to Fri, 27 Jun 2025 22:44:50 GMT -
Rating 0
- Innovation 5
- Information 8
- Rumor -3
